Pharma Securities Fraud Worries Reduced By Supreme Court Case
This article was originally published in The Pink Sheet Daily
Executive Summary
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.
You may also be interested in...
Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss
Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.
Adverse Events Disclosures May Increase After Supreme Court Ruling Against Matrixx, But "Total Mix" Matters
Companies may have to disclose adverse event reports that are not statistically significant, but the court says the amount of disclosure needed can be limited by how much a company tells the market about an issue in general.
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.